Recombinant Human G-protein coupled receptor 143 (GPR143)

What is GPR143 and what makes it unique among G protein-coupled receptors?

GPR143, encoded by the ocular albinism 1 (OA1) gene, is an atypical G protein-coupled receptor that distinguishes itself from conventional GPCRs through its intracellular localization. Unlike most GPCRs that function at the cell membrane, GPR143 is predominantly localized to endolysosomes and melanosomes, the organelles responsible for melanin synthesis and storage. This unusual subcellular localization represents a significant departure from canonical GPCR function and trafficking patterns. GPR143 is considered an orphan GPCR (oGPCR) as its precise signaling mechanisms and endogenous ligands remain incompletely characterized, though L-DOPA has been implicated as a potential ligand . The receptor's structure includes seven transmembrane domains typical of the GPCR family, with a full-length human GPR143 containing 404 amino acids as evident in recombinant expression systems .

What expression systems are available for producing recombinant human GPR143?

Several expression systems have been successfully employed for the production of recombinant human GPR143. The wheat germ in vitro expression system offers a eukaryotic cell-free platform suitable for expressing full-length GPR143 (NP_000264.1) without tags, incorporating the protein into proteoliposomes for structural and functional studies . Mammalian expression in HEK-293 cells has proven effective for producing GPR143 with various fusion tags (including His-tag) with high purity (>90% as determined by Bis-Tris PAGE) . For researchers requiring alternative approaches, cell-free protein synthesis (CFPS) systems have been used to generate GPR143 with Strep-tags, yielding proteins with approximately 70-80% purity suitable for various biochemical assays . Each system offers distinct advantages in terms of protein folding, post-translational modifications, and functional characteristics, with selection criteria dependent on specific experimental requirements and downstream applications.

What tissue expression profile does GPR143 demonstrate naturally?

GPR143 exhibits a complex tissue expression profile extending well beyond its initially recognized melanocyte-specific pattern. The most extensively characterized expression occurs in pigment-producing cells, including melanocytes of the skin and hair follicles, and the retinal pigment epithelium (RPE) of the eye . In the central nervous system, GPR143 shows region-specific expression patterns with particularly high levels in the cerebral cortex and hypothalamus, moderate expression in the olfactory bulb, hippocampus, midbrain and lower brain stem, and lower expression in the corpus striatum and cerebellum . Immunohistochemical analyses have identified GPR143-positive cells in additional brain regions including the habenular nucleus, substantia nigra, medulla oblongata, and nucleus tractus solitarius (NTS) . Outside the central nervous system, GPR143 expression has been documented in the convoluted tubules of the kidney (with abundance comparable to cerebral cortex expression), splenic capsule and red pulp, hepatocytes surrounding the hepatic vein, alveolar epithelial cells, bronchial tubes, and various smooth muscle cells . This widespread expression suggests functional roles extending far beyond melanogenesis.

How can researchers purify recombinant GPR143 while maintaining structural integrity?

Purification of recombinant GPR143 while preserving structural integrity requires specialized approaches tailored to membrane proteins. For wheat germ-expressed GPR143, incorporation into proteoliposomes using proprietary liposome technology provides a native-like lipid environment that helps maintain protein conformation . When expressed in HEK-293 cells with affinity tags (His or Strep), purification typically employs detergent solubilization followed by affinity chromatography under conditions that preserve protein structure. Quality assessment through multiple analytical techniques is essential, including Bis-Tris PAGE, anti-tag ELISA, Western blot, and analytical size exclusion chromatography (SEC) via HPLC . Researchers should validate protein integrity through both biochemical assays (e.g., ligand binding capacity) and biophysical methods (e.g., circular dichroism spectroscopy) to confirm proper folding. To minimize aggregation and denaturation, purification should be conducted at 4°C with stabilizing agents such as glycerol or specific lipids, and buffer conditions should be optimized to mimic the native environment of endolysosomes/melanosomes where GPR143 naturally functions.

What strategies can be employed to study ligand binding of recombinant GPR143 given its atypical intracellular localization?

Studying ligand binding of GPR143 presents unique challenges due to its atypical intracellular localization in endolysosomes and melanosomes. Traditional membrane-impermeable ligand binding assays are ineffective for intracellular receptors. Instead, researchers should employ permeabilized cell systems or isolated organelle preparations when working with cell-based assays. Recombinant systems offer greater flexibility, particularly when GPR143 is reconstituted into proteoliposomes with the binding pocket oriented outward . For direct binding studies, inside-out vesicle preparations can expose the ligand-binding domain to the experimental medium. Fluorescence-based techniques such as Förster Resonance Energy Transfer (FRET) have been successfully used to examine interactions between GPR143 and potential ligands like L-DOPA, especially when studying heteromeric complexes with other receptors such as α1b-adrenoceptor . Radioligand binding assays using cell-permeable compounds can be effective when combined with subcellular fractionation to isolate GPR143-containing organelles. Computational approaches, including molecular docking and molecular dynamics simulations, provide complementary strategies to predict and validate ligand binding sites on GPR143. Researchers should consider using multiple orthogonal approaches to overcome the limitations inherent to studying intracellular GPCRs.

How does heterodimerization of GPR143 with α1b-adrenoceptor influence experimental design and interpretation?

The discovery that GPR143 forms functional heteromers with α1b-adrenoceptor introduces significant complexity to experimental design and data interpretation. Researchers investigating GPR143 function must consider the potential confounding effects of endogenous α1b-adrenoceptor expression in their experimental systems. Co-immunoprecipitation studies have demonstrated that this heteromerization is enhanced by L-DOPA treatment (10-20 nM), suggesting ligand-dependent interaction dynamics . FRET and in situ proximity ligation assays have confirmed that these heteromers are functionally distinct from monomeric GPR143, with the heteromeric form exhibiting higher affinity for L-DOPA compared to the monomeric receptor . When designing recombinant expression systems, researchers should consider co-expressing both receptors at physiologically relevant ratios to better model native signaling. Control experiments should include selective antagonists of α1b-adrenoceptor to distinguish between direct GPR143 effects and those mediated through heteromer formation. The potential formation of heteromers necessitates careful interpretation of pharmacological data, as drug responses may differ between monomeric and heteromeric receptor populations. Additionally, tissue-specific expression patterns of both receptors should inform the relevance of heteromer-focused studies to particular physiological or pathological contexts, such as pulmonary hypertension where both receptors may play contributory roles .

What are the methodological considerations for studying GPR143 mutations associated with ocular albinism?

Studying GPR143 mutations associated with ocular albinism requires a systematic approach integrating molecular, cellular, and functional analyses. For recombinant expression studies, researchers should generate a panel of constructs reflecting the diversity of reported mutations (missense, nonsense, frameshift, and splicing mutations) in the OA1 gene. Expression systems should be selected based on their ability to recapitulate physiologically relevant post-translational modifications and trafficking pathways, with melanocyte or RPE cell lines offering advantages for studying cell type-specific effects. Subcellular localization analysis using confocal microscopy with organelle-specific markers is essential to determine whether mutations affect GPR143 trafficking to melanosomes/endolysosomes. Biochemical characterization should assess protein stability, glycosylation status, and ligand binding capacity of mutant receptors compared to wild-type. Functional assays should evaluate G protein coupling efficiency and downstream signaling cascades, including calcium mobilization, cAMP production, and MAPK pathway activation. For more physiologically relevant assessments, CRISPR/Cas9-mediated knock-in of specific mutations in melanocyte or RPE cell lines can provide insights into effects on melanosome biogenesis and maturation. Electron microscopy should be employed to characterize melanosome ultrastructure, as GPR143 mutations typically result in macromelanosomes. When interpreting results, researchers should consider potential compensatory mechanisms and the possibility that different mutations may cause disease through distinct molecular mechanisms.

What techniques are most effective for studying the role of GPR143 in cancer progression and metastasis?

Investigation of GPR143's role in cancer progression and metastasis requires multi-dimensional approaches spanning molecular, cellular, and in vivo techniques. Gene expression modulation through lentiviral overexpression and siRNA-mediated knockdown has successfully demonstrated that GPR143 expression levels positively correlate with melanoma cell migration capabilities . When working with recombinant GPR143, researchers should establish stable cell lines with inducible expression systems to permit precise temporal control over protein levels. Migration and invasion assays (transwell, wound healing, 3D invasion) represent critical functional readouts, while proliferation and colony formation assays address tumor growth potential. Mechanistic studies should focus on downstream signaling, particularly the RAS/RAF/MEK/ERK pathway that has been linked to GPR143-induced melanoma cell metastasis . Protein-protein interaction studies using proximity ligation assays, co-immunoprecipitation, and FRET can identify cancer-relevant binding partners. For in vivo validation, orthotopic xenograft models with GPR143-modulated cancer cells enable assessment of tumor growth and metastatic potential. Immunohistochemical analysis of patient samples should evaluate correlations between GPR143 expression and clinical outcomes, building on observations that GPR143 expression increases with progression toward metastasis in melanoma . Additionally, researchers should investigate connections between GPR143 and immune infiltration in tumors, as this correlation has been reported in cutaneous melanoma . Single-cell RNA sequencing can provide valuable insights into GPR143 expression heterogeneity within tumors and its relationship to cancer stem cell populations.

How can researchers reliably detect GPR143 in experimental systems given challenges with antibody specificity?

Reliable detection of GPR143 in experimental systems requires strategic approaches to overcome challenges with antibody specificity for this intracellular GPCR. When working with recombinant proteins, incorporation of epitope tags (His, Strep, GST) facilitates detection using well-characterized anti-tag antibodies with established specificity . For endogenous GPR143 detection, researchers should employ rigorous antibody validation through multiple complementary methods. Western blot analysis should include positive controls (recombinant GPR143), negative controls (knockout or knockdown samples), and peptide competition assays to confirm specificity. Immunofluorescence microscopy should demonstrate colocalization with established melanosomal/endolysosomal markers (LAMP1, PMEL) and show expected subcellular distribution patterns. Antibody specificity should be validated across multiple tissue types given the diverse expression profile of GPR143 . Alternative detection methods include RNAscope in situ hybridization for mRNA localization and mass spectrometry-based proteomics for protein identification in complex samples. For researchers generating new antibodies, epitope selection should carefully consider regions of GPR143 with minimal homology to other GPCRs, targeting either the N-terminal domain or specific intracellular loops. Knockout validation using CRISPR/Cas9-edited cell lines provides the most stringent control for antibody specificity. Publication of detailed validation protocols and reagent information enhances reproducibility across research groups studying this challenging receptor.

What methodology should researchers employ to investigate GPR143 signaling pathways in neuronal contexts?

Investigation of GPR143 signaling pathways in neuronal contexts requires specialized approaches that account for both the receptor's intracellular localization and the complexity of neuronal signaling networks. Primary neuronal cultures from regions with high GPR143 expression (cerebral cortex, hypothalamus) offer physiologically relevant systems, while neuronal cell lines provide more standardized alternatives for initial characterization. For recombinant studies, lentiviral vectors enabling neuron-specific promoter-driven expression are preferable to conventional transfection methods. Live-cell calcium imaging using genetically encoded calcium indicators permits real-time monitoring of signaling events in intact neurons with subcellular resolution. FRET-based sensors targeted to specific organelles (endolysosomes) can detect localized G protein activation in proximity to GPR143. Phosphoproteomic analyses following L-DOPA stimulation (10-20 nM) can comprehensively identify downstream signaling targets, while pathway-specific reporter assays provide focused readouts for canonical G protein pathways. Given GPR143's potential role in Parkinson's disease and L-DOPA response , dopaminergic neurons derived from patient-specific induced pluripotent stem cells offer valuable disease-relevant models. Chemogenetic approaches using designer receptors exclusively activated by designer drugs (DREADDs) with subcellular targeting sequences can help dissect the contribution of organelle-specific GPCR signaling. When interpreting results, researchers should consider potential cross-talk between GPR143 and other neurotransmitter receptors, particularly in brain regions where GPR143 expression overlaps with dopaminergic, angiotensinergic, and adrenergic receptor expression .

How can researchers accurately assess the potential therapeutic targeting of GPR143 in melanoma and other cancers?

Accurate assessment of GPR143 as a therapeutic target in melanoma and other cancers requires a comprehensive evaluation strategy spanning in vitro, in vivo, and clinical correlation approaches. Cancer cell line panels representing different progression stages and genetic backgrounds should be screened for GPR143 expression and correlation with invasive properties. Patient-derived xenografts and organoids offer more faithful recapitulation of tumor heterogeneity for therapeutic testing. For target validation, CRISPR/Cas9 knockout or inducible shRNA systems provide more specific GPR143 inhibition than traditional siRNA approaches. High-throughput screening platforms using GPR143-expressing cell lines can identify small molecule modulators, with counterscreens in GPR143-knockout cells to confirm specificity. Lead compounds should be evaluated for their impact on established GPR143-regulated pathways, particularly the RAS/RAF/MEK/ERK signaling cascade implicated in melanoma metastasis . Given GPR143's intracellular localization, compound design must prioritize membrane permeability to access the target. In vivo efficacy studies should utilize orthotopic tumor models with metastasis monitoring capabilities. Biomarker development should explore correlations between GPR143 expression and immune infiltration patterns , as well as potential associations with treatment resistance, building on observations of melanosome-related proteins in chemoresistant melanoma . Immunohistochemical analysis of patient samples with outcome correlation can identify patient subgroups most likely to benefit from GPR143-targeted therapies. This multi-dimensional approach provides the robust pre-clinical evidence necessary to advance GPR143-targeted therapies toward clinical development.

What techniques are most appropriate for investigating the potential role of GPR143 in L-DOPA treatment for Parkinson's disease?

Investigating GPR143's potential role in L-DOPA treatment for Parkinson's disease requires specialized techniques spanning molecular, cellular, and in vivo approaches. Recombinant GPR143 binding assays using varying concentrations of L-DOPA (1-100 nM) can establish direct interaction and binding kinetics. Co-expression systems with GPR143 and α1b-adrenoceptor are particularly important given evidence of heteromer formation enhanced by L-DOPA treatment . In neuronal models, knockdown/knockout studies can determine whether GPR143 is necessary for specific L-DOPA effects. Electrophysiological recordings in dopaminergic neurons following L-DOPA administration can assess acute effects on neuronal activity with and without GPR143 manipulation. Microdialysis in animal models can measure dopamine release patterns in response to L-DOPA under conditions of GPR143 modulation. GPR143 transgenic mouse models (both knockout and conditional knockout) treated with L-DOPA should undergo comprehensive behavioral assessment using established protocols for measuring Parkinson's-like symptoms. PET imaging with radiolabeled L-DOPA can examine whether GPR143 status affects drug distribution and metabolism in vivo. Investigation of potential neuroprotective effects should include cellular stress models and assessment of neurogenesis in the hippocampus, following reports that L-DOPA-induced neurogenesis might be mediated by GPR143 . Analysis of human post-mortem brain samples from Parkinson's patients (both L-DOPA-treated and untreated) can provide correlative evidence for GPR143 involvement. Researchers should carefully consider that GPR143-immunoreactive signals have been observed in both control and Parkinson's disease brains in the midbrain region including the substantia nigra pars compacta , suggesting complex relationships in disease pathophysiology.

What are the optimal conditions for expressing full-length recombinant human GPR143 with proper folding and functionality?

Optimizing expression of properly folded and functional recombinant human GPR143 requires careful consideration of expression systems and conditions. The wheat germ in vitro expression system has demonstrated success in generating full-length GPR143 (NP_000264.1) without tags, incorporating the protein into proteoliposomes that support native-like folding . For mammalian expression, HEK-293 cells provide appropriate post-translational modification machinery, with expression typically driven by CMV promoters in tetracycline-inducible systems that allow control over expression levels. Codon optimization specific to the expression host improves translation efficiency while fusion of GPR143 to stability-enhancing partners (SUMO, thioredoxin) can increase protein yield without compromising structure. Expression at reduced temperatures (28-30°C for mammalian cells) often improves folding by slowing production and allowing chaperones to function more effectively. Cell-free protein synthesis systems offer advantages for difficult membrane proteins, with yields of 70-80% purity for GPR143 reported . For all systems, inclusion of specific lipids during expression/purification helps stabilize the protein in a functionally relevant conformation. Functionality assessment should include ligand binding assays (with putative ligand L-DOPA), G-protein coupling analysis, and validation of proper subcellular localization in cell-based systems. Size exclusion chromatography profiles should confirm monodisperse protein populations rather than aggregates. Expression optimization typically requires systematic testing of multiple conditions, including expression duration, inducer concentration, and buffer composition, with success assessed through both yield and functional metrics specific to GPR143.

How can researchers develop reliable assays to screen for novel ligands or modulators of GPR143 activity?

Developing reliable assays for novel GPR143 ligand/modulator screening requires innovative approaches that address its intracellular localization and orphan receptor status. Cell-based reporter systems should employ melanocyte or RPE cell lines with endogenous GPR143 expression or recombinant cells with stable GPR143 expression targeted to endolysosomes/melanosomes. CRISPR/Cas9-engineered cell lines with fluorescent or luminescent tags knocked into endogenous GPR143 loci provide physiologically relevant expression levels. For direct binding assays, thermal shift assays using purified GPR143 in proteoliposomes can identify compounds that stabilize receptor conformation. Label-free technologies such as surface plasmon resonance or microscale thermophoresis using recombinant GPR143 offer advantages for initial binding characterization. Functional assays should focus on established downstream events, including MAPK pathway activation , melanosome biogenesis regulation, and calcium signaling. Bioluminescence resonance energy transfer (BRET) assays designed to detect G protein activation or β-arrestin recruitment should be adapted for intracellular compartments through appropriate targeting sequences. High-content imaging platforms can assess compound effects on melanosome morphology, number, and distribution in melanocytes or RPE cells. Virtual screening approaches using homology models of GPR143 provide computational pre-screening to prioritize compounds for experimental testing. For validation of hits, orthogonal assays and counter-screens in GPR143-knockout cells are essential to confirm target specificity. When designing compound libraries, researchers should consider the chemical properties necessary for compounds to reach intracellular compartments and include known melanogenesis modulators as reference compounds.

What experimental approaches can effectively characterize GPR143 protein-protein interactions within melanosomes and endolysosomes?

Characterizing GPR143 protein-protein interactions within melanosomes and endolysosomes requires specialized techniques that preserve the integrity of these organelles while enabling sensitive detection of interaction partners. Proximity-dependent biotinylation approaches (BioID, TurboID) with GPR143 as the bait protein can identify the proximal interactome within intact organelles in living cells. APEX2 (engineered ascorbate peroxidase) fusion to GPR143 offers an alternative proximity labeling strategy with finer temporal resolution. For validated or suspected interactions, such as with α1b-adrenoceptor , Förster Resonance Energy Transfer (FRET) and in situ proximity ligation assays provide spatial information and can detect dynamic, stimulus-dependent interactions following L-DOPA treatment. Immunoprecipitation of GPR143 from isolated melanosomes or endolysosomes followed by mass spectrometry enables unbiased interactome mapping, though careful validation is essential. Split-protein complementation assays with organelle-targeted components can confirm direct interactions in living cells. Yeast two-hybrid screening using GPR143 domains as bait can identify potential interactors, though secondary validation in mammalian cells is crucial. Co-localization studies using super-resolution microscopy techniques (STORM, PALM) can resolve protein distributions within individual organelles at nanometer resolution. For structural characterization of stable complexes, single-particle cryo-electron microscopy of purified complexes offers the potential for near-atomic resolution. When interpreting interaction data, researchers should consider the dynamic nature of endolysosomal/melanosomal compartments and validate findings across multiple cell types and experimental conditions to identify conserved interaction partners distinct from cell-specific associations.

How might single-cell technologies advance our understanding of GPR143 expression heterogeneity in different tissues?

Single-cell technologies offer unprecedented opportunities to characterize GPR143 expression heterogeneity across tissues and disease states. Single-cell RNA sequencing (scRNA-seq) can identify previously unrecognized cell populations expressing GPR143 beyond the established expression in melanocytes, RPE cells, and specific neuronal populations . This approach is particularly valuable for resolving expression differences in heterogeneous tissues like brain regions, where GPR143 shows variable expression patterns across neuronal subtypes. For protein-level analysis, mass cytometry (CyTOF) with GPR143-specific antibodies can quantify expression across thousands of individual cells while simultaneously measuring dozens of other proteins to establish correlation networks. Spatial transcriptomics techniques maintain tissue architecture information while providing single-cell resolution of GPR143 mRNA expression, critical for understanding regional variation within complex tissues. For subcellular resolution, multiplexed ion beam imaging (MIBI) or imaging mass cytometry can localize GPR143 protein within specific cellular compartments across numerous cells in tissue sections. In disease contexts, single-cell approaches can reveal shifts in GPR143-expressing cell populations that would be masked in bulk tissue analyses. For cancer research, combined single-cell genotyping and transcriptomics can correlate GPR143 expression with specific genetic alterations in individual tumor cells. Integration of single-cell data across tissues can generate a comprehensive atlas of GPR143 expression that contextualizes its diverse roles beyond pigmentation, including potential functions in neurological disorders , cancer progression , and other pathological states where GPR143-expressing cells may contribute to disease mechanisms.

What are the most promising approaches for developing GPR143-targeted therapeutics given its intracellular localization?

Developing GPR143-targeted therapeutics presents unique challenges due to its intracellular localization in endolysosomes and melanosomes, requiring innovative drug delivery strategies and mechanism-based approaches. Small molecule development should focus on membrane-permeable compounds with physiochemical properties favoring accumulation in acidic endolysosomal compartments, potentially leveraging ionizable moieties that become charged in the acidic lumen. Structure-based drug design utilizing homology models of GPR143 can guide rational development of ligands targeting key binding pockets. For biologics, engineered antibody fragments or nanobodies with cell-penetrating peptides can be designed to recognize specific epitopes on GPR143. RNA-based therapeutics, including siRNA or antisense oligonucleotides targeting GPR143 mRNA, offer an alternative approach for modulating expression levels rather than directly targeting the protein. Cell-penetrating peptides derived from GPR143 interaction interfaces can disrupt specific protein-protein interactions, such as the heteromerization with α1b-adrenoceptor . Nanoparticle-based delivery systems with endolysosomal targeting properties can improve the delivery of conventional therapeutics to GPR143-containing compartments. For melanoma applications, melanocyte-targeting strategies utilizing melanin biosynthesis pathways can enhance selective drug delivery. In neurodegenerative contexts such as Parkinson's disease, where GPR143 may play a role in L-DOPA response , blood-brain barrier penetration must be considered alongside organelle targeting. Regardless of the therapeutic modality, validation studies should employ multiple model systems with appropriate subcellular markers to confirm target engagement within the correct organellar compartments where GPR143 functions.

How can computational modeling and simulation contribute to understanding GPR143 structure-function relationships?

Computational modeling and simulation provide powerful tools for understanding GPR143 structure-function relationships in the absence of experimentally determined structures. Homology modeling using related GPCRs as templates can generate preliminary structural models of GPR143, with special consideration for its unique intracellular localization and potential ligand binding domains. These models should undergo rigorous validation through multiple scoring functions and comparison with experimental data on known GPR143 mutations associated with ocular albinism. Molecular dynamics simulations in complex membrane environments mimicking endolysosomal/melanosomal membranes can reveal dynamic conformational changes and identify stable ligand binding poses for compounds like L-DOPA. Quantum mechanics/molecular mechanics (QM/MM) approaches can provide detailed insights into potential catalytic or ligand recognition mechanisms. Structure-based virtual screening against the modeled binding pocket can identify novel potential ligands for experimental validation. Protein-protein docking simulations can predict interaction interfaces between GPR143 and partners such as α1b-adrenoceptor or components of the RAS/RAF/MEK/ERK signaling pathway implicated in melanoma progression . Network pharmacology approaches integrating protein interaction networks with GPR143 signaling pathways can identify potential points for therapeutic intervention. For experimental validation of computational predictions, site-directed mutagenesis of recombinant GPR143 at key predicted binding residues should be correlated with functional outcomes in cellular assays. Machine learning approaches integrating available experimental data on GPR143 mutations, expression patterns, and disease associations can generate testable hypotheses about structure-function relationships. As experimental structural data becomes available, iterative refinement of computational models will progressively enhance their predictive power for drug design and mechanistic understanding.

What are the most critical knowledge gaps that currently limit GPR143 research, and how might they be addressed?

Several critical knowledge gaps currently constrain progress in GPR143 research, each requiring targeted approaches to advance understanding of this atypical intracellular GPCR. The lack of a definitive three-dimensional structure represents perhaps the most fundamental limitation, as it impedes rational drug design and detailed mechanistic understanding. This gap could be addressed through intensive structural biology efforts using cryo-electron microscopy or X-ray crystallography of stabilized recombinant GPR143, potentially employing fusion proteins or antibody fragments to facilitate crystallization. The incomplete characterization of GPR143's endogenous ligand(s) and signaling mechanisms represents another major limitation, necessitating comprehensive unbiased screening approaches coupled with advanced proteomics and metabolomics to identify physiologically relevant binding partners beyond the proposed L-DOPA interaction . The precise role of GPR143 in non-pigmentary tissues remains poorly understood despite its widespread expression , requiring tissue-specific knockout models to elucidate functions in diverse contexts including neurological disorders and cancer. The mechanisms linking GPR143 dysfunction to melanosome biogenesis abnormalities in ocular albinism need further clarification through detailed molecular cell biology approaches. Additionally, the functional significance of GPR143's intracellular localization versus conventional plasma membrane GPCRs remains incompletely understood, potentially requiring targeted relocalization studies to compare signaling outcomes from different subcellular compartments. Addressing these knowledge gaps through coordinated multidisciplinary research will substantially advance both fundamental understanding of this unique receptor and its potential applications in therapeutic development for ocular albinism, melanoma, and potentially other conditions where GPR143 plays contributory roles.